FDA Approves First Interchangeable Biosimilar Product to Humira
- October 22, 2021
The Food and Drug Administration (FDA) approved October 15 Cyltezo (adalimumab-adbm) as the first interchangeable biosimilar product to reference product Humira (adalimumab), which is used to treat certain inflammatory diseases.
ARTICLE TAGS
You must be logged in to access this content.